Rho kinase inhibitors

Details Rho kinase inhibitors Rho kinase inhibitors

2007-04-03

2007-04-03

McKane, Joseph K. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S405000, C548S361100, C548S362500

Reexamination Certificate

active

10480526

ABSTRACT:
A compound represented by the formula (1):wherein R1—X— indicates that 1 to 4 R1—X— groups are present which may be the same or different,the ring A is a saturated or unsaturated 5-membered heterocyclic ring,X is a single bond, a group represented by the formula: —N(R3)—, —O— or —S—, or the like.R1is a hydrogen atom, a halogen atom, a nitro group, a carboxyl group, a substituted or unsubstituted alkyl group, or the like,R2is a hydrogen atom, a halogen atom, a nitro group, a carboxyl group, a substituted or unsubstituted alkyl group, or the like, andR3is a hydrogen atom, a substituted or unsubstituted alkyl group, or the like;a prodrug of said compound, or a pharmaceutically acceptable salt of said compound or prodrug is a useful compound as a therapeutic agent for diseases for which Rho kinase is responsible.

REFERENCES:
patent: 4143149 (1979-03-01), Wiedemann et al.
patent: 4778511 (1988-10-01), Heywang et al.
patent: 4978603 (1990-12-01), Inoue et al.
patent: 5444038 (1995-08-01), James et al.
patent: 5880151 (1999-03-01), Medina et al.
patent: 2001/0034346 (2001-10-01), Milton et al.
patent: 2003/0125344 (2003-07-01), Nagarathnam et al.
patent: 2004/0102437 (2004-05-01), Takami et al.
patent: 2 619 164 (1977-11-01), None
patent: 195238 (1986-09-01), None
patent: 61-194076 (1986-08-01), None
patent: 02-48670 (1990-02-01), None
patent: 03-254698 (1991-11-01), None
patent: 11-310568 (1999-11-01), None
patent: WO 93/18008 (1993-09-01), None
patent: WO 95/00509 (1995-01-01), None
patent: WO 00/06173 (2000-02-01), None
patent: WO 00/27819 (2000-05-01), None
patent: WO 01/56988 (2001-08-01), None
patent: WO 01/81303 (2001-11-01), None
Kwartler et al. , 1944, CAS:38:455.
Weidemann et al., 1978, CAS:88:50853.
Honjo, et al., “Effects of Rho-Associated Protein Kinase Inhibitor Y-27632 on Intraocular Pressure and Outflow Facility,” IOVS, vol. 42, No. 1, Jan. 2001, pp. 137-144.
Uehata et al., “Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension,” Nature, vol. 389, Oct. 30, 1997, pp. 990-994.
Satoh, et al., “Antiischemic Properties of Fasudil in Experimental Models of Vasopastic Angina,” Jpn J. Pharmacol. 87, 34-40 (2001).
Sato, et al., “Involvement of Rho-Kinase-Mediated Phosporylation of Myosin Licht Chain in Enhancement of Cerebral Vasopasm,” Circulation Research, Aug. 4, 2000, pp. 195-200.
Negoro, et al., “The Kinase Inhibitor Fasudil (HA-1077) Reduces Intimal Hyperplasia through Inhibiting Migratio and Enhancing Cell Loss of Vascular Smooth Muscle Cells,” Biochemical and Biophysical Research Communications 262, 211-215 (1999).
Chitaley, et al., “Antagonism of Rho-kinase stinulates rat penile erection via a nitric oxide-independent pathway,” Nature Medicine, vol. 7, No. 1, Jan. 2001, pp. 119-122.
Rees, et al., “Y-27632, A Rho-Kinase Inhibitor, Inhibits Proliferation and Adrenergic Contraction of Prostatic Smooth Muscle Cells,” The Journal of Urology, vol. 170, Dec. 2003, pp. 2517-2522.
Higashi et al., “Long-term inhibition of Rho-kinase suppresses angiotensin II-induced formation of coronary vascular lesions and cardiac hypertrophy in rats in vivo,” Circulation, 104 (17 Supplement) Oct. 23, 2001.
Abstract of Higashi et al., “Long-term inhibition of Rho-kinase suppresses angiotension II-induced formation of coronary vascular lesions and cardiac hypertrophy in rats in vivo,” Circulation, 104 (17 Supplement) Oct, 23, 2001.
Abstract of Yamagata, et al., “Effect of a calcium sensitization modulator, Y-27632, on isolated human bronchus and pulmonary artery,” Pulmonary Pharmacology & Therapeutics 13(1): 25-9, 2000.
Yamagata, et al. “Effect of a Calcium Sensitization Modulator, Y-27632, on Isolated Human Bronchus and Pulmonary Artery,” Pulmonary Pharmacology & Therapeutics (2000), 13, 25-29.

Affiliated with

Also associated with

Rating

Rho kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Rho kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Rho kinase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3724375